Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569338 | 0.92 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5572482 | 0.91 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5339407 | 0.89 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5569320 | 0.89 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5334722 | 0.87 | TUBB4A (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5778210 | 0.84 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5344499 | 0.79 | TUBB4A (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5334729 | 0.78 | TUBB4A (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL29409455 | 0.78 | TUBB4A (0.68) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5346065 | 0.78 | TUBB4A (0.68) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211588-B2 | N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation | ZENTARIS GMBH (DE) | 2007-05-01 | — | — | US | claimed |
| EP-1651600-A2 | NOVEL N -SUBSTITUTED INDOLYL-3-GLYOXYLIC ACID AMIDES, USE THEREOF AS A MEDICAMENT, AND METHOD FOR THE PRODUCTION THEREOF | Zentaris GmbH (DE) | 2006-05-03 | — | — | EP | claimed |
| WO-2005014542-A2 | NOVEL N-SUBSTITUTED INDOLYL-3-GLYOXYLIC ACID AMIDES, USE THEREOF AS A MEDICAMENT AGAINST CANCER, AND METHOD FOR THE PRODUCTION THEREOF | ZENTARIS GMBH (DE) | 2005-02-17 | — | — | WO | claimed |
| US-20050020636-A1 | N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation | ZENTARIS GMBH (DE) | 2005-01-27 | — | — | US | claimed |
| US-7211588-B2 | N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation | ZENTARIS GMBH (DE) | 2007-05-01 | — | — | US | disclosed |
| US-7211588-B2 | N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation | ZENTARIS GMBH (DE) | 2007-05-01 | — | — | US | disclosed |
| US-7211588-B2 | N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation | ZENTARIS GMBH (DE) | 2007-05-01 | — | — | US | disclosed |
| US-20050020636-A1 | N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation | ZENTARIS GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020636-A1 | N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation | IDO2, IDO1, AGXT | TUBB4A 585/4885TUBB 391/4885TUBA3C 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.